Bone Tissue-Engineered Implants Using Human Bone Marrow Stromal Cells: Effect of Culture Conditions and Donor Age
At present, it is well known that populations of human bone marrow stromal cells (HBMSCs) can differentiate into osteoblasts and produce bone. However, the amount of cells with osteogenic potential that is ultimately obtained will still be dependent on both patient physiological status and culture s...
Saved in:
Published in | Tissue engineering Vol. 8; no. 6; pp. 911 - 920 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Mary Ann Liebert, Inc
01.12.2002
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | At present, it is well known that populations of human bone marrow stromal cells (HBMSCs) can differentiate into osteoblasts and produce bone. However, the amount of cells with osteogenic potential that
is ultimately obtained will still be dependent on both patient physiological status and culture system. In addition, to use a cell therapy approach in orthopedics, large cell numbers will be required and,
as a result, knowledge of the factors affecting the growth kinetics of these cells is needed. In the present study we investigated the effect of dexamethasone stimulation on the
in vivo
osteogenic
potential of HBMSCs. After a proliferation step, the cells were seeded and cultured on porous calcium phosphate scaffolds for 1 week, and then subcutaneously implanted in nude mice for 6 weeks, in order
to evaluate their
in vivo
bone-forming ability. Furthermore, the effect of donor age on the proliferation rate of the cultures and their ability to induce
in vivo
bone formation was studied.
In 67% of the assayed patients (8 of 12), the presence of dexamethasone in culture was not required to obtain
in vivo
bone tissue formation. However, in cultures without bone-forming ability or with
a low degree of osteogenesis, dexamethasone increased the bone-forming capacity of the cells. During cellular proliferation, a significant age-related decrease was observed in the growth rate of cells from
donors older than 50 years as compared with younger donors. With regard to the effect of donor age on
in vivo
bone formation, HBMSCs from several donors in all age groups proved to possess
in
vivo
osteogenic potential, indicating that the use of cell therapy in the repair of bone defects can be applicable irrespective of patient age. However, the increase in donor age significantly decreased
the frequency of cases in which bone formation was observed. |
---|---|
Bibliography: | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
ISSN: | 1076-3279 1557-8690 |
DOI: | 10.1089/107632702320934010 |